Aurinia Pharmaceuticals (NASDAQ:AUPH) Hits New 12-Month High – Should You Buy?

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $16.20 and last traded at $14.4550, with a volume of 2219594 shares. The stock had previously closed at $13.17.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AUPH. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada increased their price objective on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $13.00.

Aurinia Pharmaceuticals Price Performance

The business has a 50-day moving average price of $12.10 and a 200 day moving average price of $10.01. The company has a market cap of $1.91 billion, a price-to-earnings ratio of 33.83 and a beta of 1.25. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. As a group, research analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Institutional Trading of Aurinia Pharmaceuticals

Hedge funds have recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,744 shares in the last quarter. MAI Capital Management purchased a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at $39,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at $60,000. Xponance Inc. purchased a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at $82,000. Finally, Kazazian Asset Management LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at $84,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.